Background
==========

Dopamine is one of the major modulatory neurotransmitters in the central nervous system (CNS) \[[@B1]\]. As dysfunction of dopaminergic neurotransmission in the CNS has been implicated in development of PD \[[@B2]\], it has been suggested that genetic polymorphisms involved in the biosynthesis and degradation of dopamine and related compounds influence susceptibility to PD. Catechol-O-methyltransferase (COMT) is an enzyme, which by methylation inactivates neurotransmitters and toxic catechols such as the immediate precursor of dopamine. Monoamine oxidase B (MAOB) is one of the primary enzymes regulating metabolism of neurotransmitters such as dopamine. There are five known dopamine receptors (DRD1-5) grouped into D-1 like (DRD1 and DRD5) and D-2 like (DRD2, DRD3 and DRD4) receptors based on their pharmacological profiles and sequence homology. Of these, DRD2 and DRD4 govern the signaling effect and modulate the motor behavior and activity of nigrostriatal neurons \[[@B3]\]. Genetic variation in these proteins, which are responsible for dopaminergic neurotransmission, may influence susceptibility to PD.

Decreased COMT activity may result in increased metabolism of dopamine to neuromelanin that can enhance the formation of cyototoxic radicals contributing to neuronal degeneration \[[@B4]\]. As the A allele of *COMT*rs4680 is associated with low COMT activity of soluble COMT \[[@B5]\], the A allele of *COMT*rs4680 may be linked to an increased risk of PD. It has been suggested that MAOB inhibition may prevent degeneration of the dopaminergic system in PD \[[@B6]\]. It is well-documented that cigarette smoking is associated with reduced MAOB activity and confers beneficial effects against PD \[[@B7]\]. Therefore, low MAOB activity may play a preventive role in PD development. Although the *MAOB*rs1799836 polymorphism is a synonymous substitution, this single nucleotide polymorphism (SNP) is associated with varying enzyme activity. In fact, synonymous SNPs can cause inactivation of the native splicing donor site, which results in a premature stop codon or exon skipping, yielding a shorter mRNA \[[@B8]\]. The shorter mRNA results in a truncated protein that is likely rapidly degraded or functionally inactive \[[@B9]\]. As the G allele of *MAOB*rs1799836 polymorphism is associated with lower activity of brain MAOB activity \[[@B10]\], the G allele may be involved in PD susceptibility (protective). The *DRD2*rs1800497 T allele (formerly *DRD2*TaqI A1) showed reduced DRD2 density in the postmortem brain \[[@B11]\], decreased receptor binding in positron emission tomography *in vivo*\[[@B12]\] and reduction of dopaminergic activity in the CNS \[[@B13]\]. However, the impact of *DRD2*rs1800497 on D2 receptor density has recently been questioned \[[@B14]\]. The functional significance of *DRD2*rs1800497 is not clear at this time, and there may be linkage disequilibrium between the other polymorphisms. The *DRD4*rs1800955 SNP is thought to influence promoter activity with the T allele exhibiting a 40% reduction in promoter activity relative to the C allele *in vitro*\[[@B15]\]. As the T allele of *DRD4*rs1800955 is considered to be involved in defects in dopaminergic neurotransmission, the T allele may play a deleterious role in PD development.

Studying gene-environment interactions in relation to PD risk may be valuable because positive findings would clearly implicate disease-causing exposures, clarify PD etiology, and elucidate environmental modifications for disease prevention. This study aimed to determine the impact of polymorphisms involved in dopaminergic neurotransmission on PD risk alone or in combination with smoking in a Japanese population.

Methods
=======

Study subjects
--------------

PD patients were recruited at three university hospitals and one national hospital in Fukuoka Prefecture, a metropolitan area of Kyushu Island in southern Japan, and in three university hospitals, three national hospitals and one municipal hospital in Osaka, Kyoto, and Wakayama Prefectures. Eligible (prevalent) cases were patients who were within 6 years of the onset of PD and who presented at one of the 11 collaborating hospitals between April 1, 2006 and March 31, 2008. The mean duration (± SD) of PD was 38.8 (16.7) months. The mean age of onset (± SD) was 65.76 (± 8.82) years. There were no patients with juvenile PD. During the same period, hospital controls, without a previous diagnosis of a neurodegenerative or malignant disease, were recruited from departments other than the department of neurology because hospital controls are more motivated and are more easily accessible for obtaining DNA samples. Controls were not, individually or in larger groups, matched to cases. Details of the study subjects have been documented elsewhere \[[@B13]\].

Six hundred and eleven subjects (240 PD patients and 371 controls) agreed to donate buccal samples. Data on smoking and pesticide use were insufficient for two cases and one control. In total, 238 cases and 369 controls were enrolled in this study. The ethics committees of the eleven collaborating universities/hospitals approved the research protocol, and all subjects signed informed consent.

Genetic analysis
----------------

Genomic DNA was extracted from buccal samples. Genetic determinations were blinded to PD status. TaqMan SNP Genotyping Assays (ABI) were used for the following (gene, SNP, assay ID): *COMT*, rs4680, C_25746809_50; *MAOB*, rs1799836, C_8878790_10; *DRD2*, rs1800497, C_7486676_10; *DRD4*, rs1800955, C_7470700_30.

Statistical analysis
--------------------

To test for associations between SNPs and PD, we defined the ancestral allele using the National Center for Biotechnology Information SNP database as the major allele. We assessed Hardy-Weinberg equilibrium (HWE) via a goodness-of-fit χ^2^test (Pearson) to compare the observed and expected genotype frequencies among controls. Based on the results from functional studies (SNPs other than *DRD2*rs1800497) and our results of associations between SNPs and PD, we designated the genotype presumed to increase the risk of PD as the \"at-risk\" genotype. The trend of association was assessed by a logistic regression model assigning ordinal scores to the levels of the independent variable. As *MAOB*is located on the X chromosome (Xp11.23), the genotypes were assessed separately in men and women. Although men are in a hemizygous state, the genotypes of *MAOB*rs1799836 for men were coded as homozygous. All \"at-risk\" alleles were classified into six categories (0-2 and 3, 4, 5, 6, and 7+). Alternatively, all \"at-risk\" alleles were classified into four categories (0-3 and 4, 5, 6 +). Unconditional logistic regression was used to compute the odds ratios (ORs) and their 95% confidence intervals (CIs), with adjustments for potential confounders. The potential confounders included age (continuous variable), sex (male/female), region of residence (Fukuoka/Kinki), smoking status (ever/never), alcohol consumption \[long-term consumption of alcoholic beverages (continuing consuming for ≥49 years, which is a cutoff point at the 90th percentile of controls)/short-term consumption of alcoholic beverages (continuing consuming for \< 49 years)\] and pesticide, herbicide or fungicide exposure (ever/never). Modeling different mechanisms of action of a particular allele was conducted by grouping individuals with one or two particular genotypes regarding the chosen model (dominant model: scored as 1 for heterozygous and homozygous of the possible risk allele for PD and 0 otherwise; recessive model: scored as 1 for homozygous of the possible risk allele for PD and 0 otherwise). The interaction between SNPs and cigarette smoking on the risk of PD was statistically evaluated based on the likelihood test, comparing the models with and without a term for interaction (multiplicative scale).

All statistical analyses were implemented in STATA Version 10.1. All P values were two-sided, with those less than 0.05 considered statistically significant.

Results
=======

The distributions of selected characteristics among subjects are summarized in Table [1](#T1){ref-type="table"}. Two hundred and thirty-eight patients with PD and 369 controls were enrolled in the study. The sex ratio, the prevalence of first degree family history of PD and the region of residence did not differ significantly between cases and controls. Compared with control subjects, cases were more likely to be older (P = 0.007) and report long-term alcohol consumption (P = 0.041). PD patients were less likely to report a history of smoking compared to the control subjects (P \< 0.0001). Unexpectedly, the PD patients tended to have less frequent home or occupational pesticide exposure.

###### 

Selected characteristics of Parkinson\'s disease cases and controls

  Characteristics                     Cases (n = 238)      Controls (n = 369)   *P*
  ----------------------------------- -------------------- -------------------- -----------
  Age, year (95% CI)                  68.5 (67.4 - 69.6)   66.6 (65.7 - 67.4)   0.007
  Sex, n (%)                                                                    
   Male                               91 (38.2)            140 (38.0)           
   Female                             147 (61.8)           228 (62.0)           0.96
  First degree family                                                           
   history of PD, n (%)               11 (4.62)            12 (3.25)            0.39
  Smoking status, n (%)                                                         
   Current smoker                     7 (2.94)             50 (13.6)            
   Former smoker                      57 (24.0)            97 (26.3)            
   Non-smoker                         174 (73.1)           222 (60.2)           \< 0.0001
  Consumption of alcoholic                                                      
   beverages, n (%)\*                                                           
   Short-term                         195 (81.9)           320 (87.9)           
   Long-term                          43 (18.1)            44 (12.1)            0.041
  Home pesticide use, n (%)                                                     
   Yes                                117 (49.2)           202 (54.7)           
   No                                 121 (50.8)           167 (45.3)           0.18
  Occupational pesticide use, n (%)                                             
   Yes                                20 (8.4)             33 (8.9)             
   No                                 218 (91.6)           336 (91.1)           0.82
  Either home or occupational                                                   
  pesticide use, n (%)                                                          
   Yes                                122 (51.3)           210 (56.9)           
   No                                 116 (48.7)           159 (43.1)           0.17
  Region of residence, n (%)                                                    
   Fukuoka                            89 (37.4)            154 (41.7)           
   Kinki                              149 (62.6)           215 (58.3)           0.29

95% CI, 95% confidence interval

Five cases were missing.

The distributions of polymorphisms involved in dopaminergic neurotransmission among cases and controls are shown in Table [2](#T2){ref-type="table"}. Four SNPs did not deviate from HWE in controls (P~HWE~= 0.077 for *COMT*rs4680, P~HWE~= 0.443 for *MAOB*rs1799836 among women, P~HWE~= 0.111 for *DRD2*rs1800497, P~HWE~= 0.083 for *DRD4*rs1800955). As *MAOB*is located on the X chromosome, rs1799836 among men (no heterozygotes) and women combined deviated from HWE. There were nonsignificant differences in genotypic frequencies between case and control subjects for all of the polymorphisms (P = 0.106 - 0.460). The AA genotype of *COMT*rs4680 was marginally associated with an increased risk of PD compared with the GG genotype (OR = 1.86, 95% CI = 0.98 - 3.50). There was a significant trend in increasing risk with the number of the A alleles of *COMT*rs4680 (P~trend~= 0.044). A dominant effect of the A allele on PD risk was suggested. Subjects with the AA genotype had a significantly increased risk of PD compared with those with at least one G allele (adjusted OR = 1.70, 95% CI = 1.12 - 2.58). There was a significant trend in decreasing risk with the number of the G alleles of *MAOB*rs1799836 (P~trend~= 0.016). A recessive effect of the A allele of *MAOB*rs1799836 on PD risk was suggested. The C allele of *DRD2*rs1800497 was associated with an increased risk of PD and appeared to act in a recessive mode in this study. Similarly, the T allele of *DRD4*rs1800955 was regarded as the putative risk allele and appeared to behave in a dominant fashion.

###### 

Associations of polymorphisms involved in dopaminergic neurotransmission and Parkinson\'s disease

  ---------------------------------------------------------------------------------
  Polymorphism          Cases (%)\   Controls (%)\     P       Adjusted\* OR\
                        (n = 238)    (n = 369)                 (95% CI)
  --------------------- ------------ ----------------- ------- --------------------
  *COMT*rs4680                                                 

   GG (ancestral)       98 (41.2)    179 (48.5)                1.0

   GA                   116 (48.7)   166 (45.0)                1.26 (0.88 - 1.79)

   AA                   24 (10.1)    24 (6.5)          0.106   1.86 (0.98 - 3.50)

                                     P~HWE~= 0.077             P~trend\ =~0.044

   GA + AA vs. GG       140 (58.8)   190 (51.4)                1.33 (0.95 - 1.87)

                                                               

  *MAOB*rs1799836                                              

   AA (A) (ancestral)   192 (80.7)   273 (74.0)                1.0

   AG                   34 (14.3)    68 (18.4)                 0.61 (0.37 - 0.99)

   GG (G)               12 (5.0)     28 (7.6)                  0.55 (0.26 - 1.16)

                                     P~HWE~\< 0.0001   0.154   P~trend\ =~0.016

   AA (A) vs. AG +\                                            1.70 (1.12 - 2.58)
  GG (G)                                                       

  Female                                                       

   AA (ancestral)       110 (74.8)   156 (68.1)                1.0

   AG                   34 (23.1)    68 (29.7)                 0.60 (0.36 - 0.99)

   GG                   3 (2.13)     5 (2.18)                  0.90 (0.21 - 3.97)

                                     P~HWE~= 0.443     0.368   P~trend\ =~0.084

  Male                                                         

   A                    82 (90.1)    117 (83.7)                1.0

   G                    9 (9.89)     23 (16.3)         0.166   0.45 (0.19 - 1.09)

                                                               

  *DRD2*rs1800497                                              

   TT (ancestral)       29 (12.2)    52 (14.1)                 1.0

   TC                   117 (49.2)   192 (52.0)                1.04 (0.61 - 1.77)

   CC                   92 (38.7)    125 (33.9)        0.460   1.32 (0.77 - 2.28)

                                     P~HWE~= 0.111             P~trend\ =~0.204

   CC vs. TC + TT                                              1.28 (0.90 - 1.82)

                                                               

  *DRD4*rs1800955\*\*                                          

   TT (ancestral)       81 (34.0)    136 (37.0)                1.0

   TC                   122 (51.3)   162 (44.0)                1.23 (0.85 - 1.79)

   CC                   35 (14.7)    70 (19.0)         0.173   0.88 (0.54 - 1.47)

                                     P~HWE~= 0.083             P~trend\ =~0.928

   TT + TC vs. CC                                              1.27 (0.80-2.00)
  ---------------------------------------------------------------------------------

\*Adjusted for age, sex, first degree family history of PD, region, smoking status, drinking status and pesticide exposure.

\*\*One control was missing.

We assessed interactions between polymorphisms involved in dopaminergic neurotransmission and smoking (Table [3](#T3){ref-type="table"}). To achieve adequate statistical power, current and former smokers were combined (ever smokers). The OR of a history of smoking was 0.40 (95% CI = 0.25 - 0.64) after adjustment for age, sex, first degree family history of PD, region, alcohol consumption and pesticide use (data not shown). As shown in Table [3](#T3){ref-type="table"}, non-smokers with at least one A allele of *COMT*rs4680 (adjusted OR = 3.97, 95% CI = 2.13 - 7.41) had a higher risk of PD than those with the GG genotype (adjusted OR = 3.70, 95% CI = 1.95 - 7.02), relative to ever smokers with the GG (non-risk) genotype (reference). Ever smokers with the GA and AA genotypes combined had a significantly increased risk of PD (adjusted OR = 2.19, 95% CI = 1.17 - 4.10). Evidence of interaction between the *COMT*rs4680 genotypes and smoking was suggested (P = 0.061). Similarly, non-smokers with the \"at-risk\" AA genotype of *MAOB*rs1799836 (adjusted OR = 5.74, 95% CI = 2.16 - 15.2) had a higher risk of PD than those with the AG and GG genotypes combined (adjusted OR = 3.68, 95% CI = 1.30 - 10.4), relative to ever smokers with the AG and GG genotypes combined. Smokers with the AA genotype presented a nonsignificantly increased risk of PD (adjusted OR = 2.39, 95% CI = 0.91 - 6.27). Interaction between the *MAOB*rs1799836 genotypes and smoking was far from significant. As for the *DRD2*rs1800497 and *DRD4*rs1800955 SNPs, the significantly high ORs were attributed largely to the effect of non-smoking. The interaction measure between smoking and either *DRD2*rs1800497 or *DRD4*rs1800955 did not reach statistical significance.

###### 

Interaction between smoking and polymorphisms involved in dopaminergic neurotransmission in Parkinson\'s disease

  Polymorphism    Genotype                   Non-smokers   Ever smokers         P*~inteaction~*                        
  --------------- -------------------------- ------------- -------------------- ----------------- -------------------- -------
  *COMT*          No risk† (GG)              77/103        3.70 (1.95 - 7.02)   21/76             1.0 (reference)      0.061
  rs4680          At-risk† (GA + AA)         97/119        3.97 (2.13 - 7.41)   43/71             2.19 (1.17 - 4.10)   
  *MAOB*          No risk‡ \[GG (G) + AG\]   40/70         3.68 (1.30 - 10.4)   6/26              1.0 (reference)      0.434
  rs1799836       At- risk‡ \[AA (A)\]       134/152       5.74 (2.16 - 15.2)   58/121            2.39 (0.91 - 6.27)   
  *DRD2*          No risk‡ (TC + TT)         108/153       2.32 (1.34 - 3.99)   38/91             1.0 (reference)      
  rs1800497       At- risk‡ (CC)             66/69         3.16 (1.75 - 5.70)   26/56             1.12 (0.61 - 2.08)   0.608
  *DRD4*          No risk† (CC)              25/37         2.98 (1.18 - 7.56)   10/33             1.0 (reference)      
  rs1800955\*\*   At- risk† (TT + TC)        149/184       3.50 (1.57 - 7.80)   54/114            1.48 (0.67 - 3.28)   0.637

\*Adjusted for age, sex, first degree family history of PD, region, drinking status and pesticide exposure.

\*\*One control was missing.

† Based on the dominant model.

‡ Based on the recessive model.

There were no polymorphism-polymorphism interactions in any possible combination (data not shown).

We examined the cumulative effect of putative \"at-risk\" alleles of four SNPs involved in dopaminergic neurotransmission on PD risk (Table [4](#T4){ref-type="table"}). Increasing numbers of putative \"at-risk\" alleles increased PD risk in a dose dependent manner (P~trend~= 0.007). The risk was more than doubled in subjects with seven or eight putative \"at-risk\" alleles (adjusted OR = 2.66, 95% CI = 1.03 - 6.88), compared to those with one or two putative \"at-risk\" alleles. Alternatively, for carriers with more than five putative \"at- risk\" alleles, PD risk was increased \~2-fold (OR = 1.80, 95% CI = 1.07 - 3.05), compared with carriers with less than or equal to three putative \"at- risk\" alleles.

###### 

Relationship of total number of \"at-risk\" genotypes of polymorphisms involved in dopaminergic neurotransmission to Parkinson\'s disease

  -----------------------------------------------------------------------------------------------------------------------------------
  Number of \"at-risk\"\*\   Subjects, n (%)   Adjusted† OR (95% CI)                                             
  alleles                                                                                                        
  -------------------------- ----------------- ----------------------- -------------------- -------------------- --------------------
  0                          0 (0.0)           0 (0.0)                 \-                   \-                   \-

  1                          2 (0.84)          6 (1.63)                1.0 (reference)      1.0                  

  2                          8 (3.36)          16 (4.35)               1.41 (0.22 - 9.06)   (reference)          1.0 (reference)

  3                          25 (10.5)         46 (12.5)               1.59 (0.29 - 8.74)   1.23 (0.49 - 3.09)   

  4                          51 (21.4)         100 (27.2)              1.65 (0.31 - 8.78)   1.28 (0.54 - 2.99)   1.10 (0.64 - 1.90)

  5                          73 (30.7)         107 (29.1)              2.13 (0.41 - 11.2)   1.64 (0.71 - 3.79)   1.42 (0.85 - 2.39)

  6                          51 (21.4)         65 (17.7)               2.39 (0.45 - 12.7)   1.84 (0.78 - 4.36)   

  7                          25 (10.5)         26 (7.07)               3.47 (0.62 - 19.4)   2.66                 1.80 (1.07 - 3.05)

  8                          3 (1.26)          2 (0.54)                3.25 (0.28 - 37.8)   (1.03 - 6.88)        

                                                                       *P~trend~*= 0.007    *P~trend~*= 0.007    *P~trend~*= 0.012
  -----------------------------------------------------------------------------------------------------------------------------------

\* Based on our results, we designated the allele that is presumed to increase the risk of PD as the \"at-risk\" allele.

\*\*One control was missing.

†Adjusted for age, sex, first degree family history of PD, region, smoking status, drinking status and pesticide exposure.

Discussion
==========

The polymorphisms involved in dopaminergic neurotransmission such as *COMT*rs4680, *MAOB*rs1799836, *DRD2*rs1800497 and *DRD4*rs1800955 were determined in a total of 607 Japanese subjects (238 PD cases and 369 controls). As compared with the GG genotype of *COMT*rs4680, the AA genotype was marginally associated with an increased risk of PD. The AA genotype of *COMT*rs4680 has been reported to be a genetic risk factor for PD in Japanese populations \[[@B16],[@B17]\] but the studies among ethnic populations other than Japanese failed to confirm any significant association \[[@B5],[@B18]-[@B25]\]. This ethnic difference might be partly due to the difference in the allelic frequency of *COMT*rs4680. According to the HapMap SNP database \[[@B26]\], the A allele frequency is more common among Caucasians (51.7%) and less common among Japanese (23.3%), Han Chinese (25.6%) and Yorubas (a West African ethnic group, 29.2%). The frequency of the A allele in this study (29.0%) was somewhat higher than that of the HapMap SNP database but similar to that of other Japanese populations (28.8% and 31.1%) \[[@B16],[@B17]\]. Generally, the low frequency of the \"at risk\" allele reduces the statistical power. As the prevalence of the A allele was lower in Japanese than in Caucasians, this is not the case. Given the lower frequency of the A allele in Japanese subjects, if this allele is associated with an increased risk of PD, then the prevalence of PD would be lower among Japanese than Caucasians. In fact, the prevalence of PD is generally lower in Asian and African-American populations than in Caucasian populations \[[@B27],[@B28]\]. The reason why Japanese studies found a significant association between *COMT*rs4680 and PD risk is not clear. The ethnic difference may reflect different gene-environment interactions, gene-gene interactions, or different linkages to the polymorphisms determining PD risk.

As compared with individuals with at least one G allele of *MAOB*rs1799836, those with the AA genotype had a significantly increased risk of PD. A number of studies have examined *MAOB*rs1799836 and PD risk with conflicting results. Some studies reported that the G allele of *MAOB*rs1799836 was significantly associated with an increased risk of PD \[[@B22],[@B29],[@B30]\]. Similarly, the presence of the G allele was associated with a modest increased risk of PD \[[@B22],[@B25],[@B31]\]. On the contrary, a significant association between the A allele of *MAOB*rs179986 and an increased PD risk was observed \[[@B32]\]. Other studies found no association between this polymorphism and PD risk \[[@B23],[@B24],[@B33]-[@B36]\]. A meta-analysis based on six studies published before November 1999 reported that there was no significant association of *MAOB*rs1799836 with PD \[[@B37]\]. Each population may have its own set of environmental and genetic factors that contribute to PD risk. The lack of replication can in part be accounted for as the role of *MAOB*rs179986 on PD risk differs with environmental factors such as smoking.

The *DRD*2 rs1800497 and *DRD4*rs1800955 SNPs were not associated with PD risk in this study. No significant association of *DRD2*rs1800497 and PD risk has been reported in different populations \[[@B30],[@B36],[@B38]-[@B40]\]. However, two studies of Caucasians found that the T allele of *DRD2*rs1800497 was associated with a significantly increased risk of PD \[[@B41],[@B42]\]. As the conflicting results may be attributed to linkage disequilibrium (LD) between the other polymorphisms, there is a possibility that other polymorphisms such as -141 Ins/Del (rs1799732), Ser311Cys (rs1801028), Taq IB (rs1079597) and C957T (rs6277), which may be in LD with rs1800497, may play a causative role in PD development. The differences in LD would be observed among different populations \[[@B43]\] and different historical stages of the same population \[[@B44]\]. Therefore, it is more likely that the ethnic differences of the association between *DRD2*rs1800497and PD exist. As reproducibility of the results is important in genetic association studies, additional studies with a large sample size are needed to clarify the pivotal role of *DRD2*rs1800497 in PD development. Furthermore, the association of the T allele of *DRD2*rs1800497 with receptor availability was not always replicated. Future mechanistic studies are needed to verify the functional significance of different *DRD2*rs1800497 alleles. To the best of our knowledge, no studies on the association between *DRD4*rs1800955 and PD have been previously reported. PD risk associated with the 48 bp tandem repeat polymorphism of *DRD4*at the third exon, which may also be functional, has been evaluated, and one \[[@B45]\] of four studies \[[@B45]-[@B48]\] found a significant association. This tandem repeat polymorphism is probably not the main determinant in developing PD. Again, testing replication in different populations is an important step. Additional studies are warranted to corroborate the null association among Japanese samples suggested in the present study.

It is widely accepted that PD development requires environmental factors acting on a genetically predisposed individual. A gene-environment interaction was suggested, with the GA and AA combined genotype of *COMT*rs4680 and non-smoking conferring significantly higher risk (OR = 3.97, 95% CI = 2.13 - 7.41), compared with the GG genotype and a history of smoking (P for interaction = 0.061). In other words, the impact of the combined genotype of GA and AA on PD risk was marginally different between ever smokers (2.19) and non-smokers (3.97/3.70 = 1.07). In contrast to our results, two studies have reported no interaction between cigarette smoking and *COMT*rs4680 in relation to PD risk \[[@B23],[@B25]\]. Our results suggest that interaction between *COMT*rs4680 and smoking is likely to vary in different races. Additional epidemiological studies are warranted to determine the smoking-*COMT*polymorphism interaction. There were no interactions between *MAOB*rs1799836, *DRD2*rs1800497 or *DRD4*rs1800955 polymorphisms and smoking. Conflicting results regarding the modifying effect for *MAOB*rs1799836 on PD risk have been reported. *MAOB*rs1799836 modified the association between PD risk and smoking \[[@B31],[@B49]\]. A significant interaction was observed in men but not in women \[[@B50]\]. Several studies, including the studies with the same data or overlapping data by the overlapping authors \[[@B23],[@B39]\], also reported no interaction between *MAOB*rs1799836 and smoking in PD risk \[[@B23],[@B35],[@B36],[@B39]\]. Other environmental factors may reduce MAOB and such phenotypic determinants may vary across populations. Given the possibility of environmental effects on MAOB activity, further work on interactions between the *MAOB*polymorphism and smoking is needed. There was no interaction between smoking and *DRD2*rs180049 in two studies \[[@B36],[@B39]\]. No studies examining the interactions between smoking and the *DRD4*rs1800955 in PD have been published to date. Ethnicity might also play a role when studying the role of genetic factors in the association between smoking and PD.

Accumulation of multiple \"at-risk\" alleles markedly increased the risk of PD in a dose dependent manner, although each \"at-risk\" allele was associated with a small increase in risk (Table [4](#T4){ref-type="table"}). Thus, individuals may have several nonsignificant \"at-risk\" genotypes\" whose combined effect results in a high-risk. Compared with known nongenetic risk factors, smoking (1/0.40 = 2.50) and a combination of \"at-risk\" alleles (2.66, seven or eight \"at-risk\" alleles vs, less than four \"at-risk\" alleles) provided the same impact in PD risk prediction. Our study therefore suggests that the combined effect of multiple variant alleles may be more important than the investigation of a SNP in modulating PD risk although \"at-risk\" allele combinations are rare in the general population. However, although an \"at-risk\" allele (genotype) may confer a small individual risk, this small increase in risk translates to a large number of excess PD cases in the population. Therefore, the polymorphisms, even those not significantly associated with PD, should be considered an important public health issue.

One strength of our study is that cases were identified according to strict diagnostic criteria, and thus the possibility of misclassification of PD is negligible. Several limitations of the study also warrant mention. Our study may have included a bias due to the self-reporting of smoking habits. However, discrepancies between self-reported smoking habits and biochemical verification are minimal among the general population \[[@B51],[@B52]\]. Another problem with case-control studies is recall bias. As risk factors for PD are poorly characterized, study subjects have few systematic preconceived ideas regarding their disease etiology. Any recall bias was likely to be non-differential given the many pesticides reported, the complex temporal pattern of their use, and the fact that subjects were not informed of the study hypotheses.

Conclusions
===========

Our results suggest that the *MAOB*rs1799836 played an important role in PD susceptibility in our Japanese population. To the best of our knowledge, this is the first report on the relationship between *DRD4*rs1800955 with PD. Our study provides evidence of the interaction between *COMT*rs4680 polymorphisms and smoking. The previous studies have failed to confirm any significant association between PD and rs1799836/rs4680 \[[@B53]\], however. Replication of findings is very important before any causal inference can be drawn. In order to confirm our findings, consortia of investigators working on PD may need to be established. Future studies involving larger control and case populations and better pesticide exposure histories will undoubtedly lead to a more thorough understanding of the role of the polymorphisms involved in dopaminergic neurotransmission in PD development.

Appendix
========
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